Intuitive Surgical stock dubbed a ‘premier, high-growth' name despite first sell rating

Intuitive Surgical (ISRG) received its first "sell" rating from Deutsche Bank, citing concerns over increasing competition from remanufactured tools and a lowered price target to $440, implying a 15% downside. This contrasts with Jim Cramer's bullish stance, who views ISRG as a "premier, high-growth" company with a successful "razor-and-blade" business model, and Hightower's Stephanie Link, who considers the stock a secular grower in healthcare and attractive at current valuations despite a projected decrease in gross profit margin due to tariffs.

Analysis

Intuitive Surgical (ISRG) faces a notable shift in analyst sentiment, marked by Deutsche Bank's first "sell" rating and a $440 price target, implying over 15% potential downside due to anticipated headwinds from more affordable remanufactured tools threatening its "da Vinci" robot system. This contrasts sharply with continued bullishness from prominent figures like Jim Cramer, who esteems ISRG as a "premier, fast-growing company" with a robust "razor-and-blade" business model and a strong historical performance, citing it as one of the best stock charts over the past two decades. Similarly, Hightower's Stephanie Link recently increased her position, viewing ISRG as a "secular grower in healthcare" and finding its valuation attractive given the stock is currently down over 10% from its year-to-date high. Despite reporting first-quarter financials that surpassed Street estimates, the company projects its adjusted gross profit margin to be capped at 66.5% this year, a decrease from over 69% in 2024, partly attributed to new tariffs. The stock's current pullback and lack of dividend payments present a mixed picture for different investor profiles.

Key Decisions for Investors

• Investors should critically assess the divergence between Deutsche Bank's competitive concerns and the bullish outlook from other market commentators, particularly regarding the long-term viability of the 'razor-and-blade' model.
• Monitor upcoming earnings reports for data on procedure volumes, the realized impact of remanufactured tool competition on sales and margins, and specific management commentary addressing the tariff effects on gross profit margins.
• Consider the current valuation, with the stock down over 10% from its year-to-date peak, as a potential entry point for growth-focused portfolios, while acknowledging the absence of dividend yield may make it unsuitable for income-oriented investors.